27 January 2026   Despite important investment in biomedical research, the most common malignant adult brain tumor - glioblastoma (GBM) - remains largely refractory to existing treatments. Tumors can evade or suppress immunity through a variety of mechanisms, including antigen heterogeneity and  immunosuppressive signaling. Owing in large part to inter-species differences in the immune system and the tumor microenvironment (extracellular matrix composition, stromal cells beha

17 October 2025   Neurodegenerative disorders, such as Alzheimer’s disease  (AD), are highly debilitating, progressive disorders that affect cognitive function and behaviour. Traditionally, biomedical research into AD has relied on animals to model AD pathophysiology and develop treatments. However, none of the treatments tested in AD animal models were able to halt or reverse cognitive decline in AD patients. The failure rate in clinical trials of drugs developed and validat

17 October 2025   Hesperos Inc. has been awarded  a Phase IIB SBIR grant from the National Institute on Aging to investigate the effects of medication on cognitive impairment.   In humans, drug-induced cognitive decline may arise from subtle network‑level disruption, synaptic dysfunction, neurotransmitter imbalance and moderate neuroinflammation. However, these effects are very challenging to detect using standard in vitro models and animal testing. Cognitive decline is typic